LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
| Image |  |
|---|---|
| Description | scientific article published on 18 October 2014 |
| Author/s | |
| Publication date | October 18, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |